Accessibility Statement Skip Navigation
  • Back to Global Sites
  • +971 (0) 4 368 1644
  • GDPR
  • Journalists
  • Send a Release
PR Newswire: news distribution, targeting and monitoring
  • News
  • Products
  • Contact
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • Telephone

    • +971 (0) 4 368 1644 from 8 AM - 5:30 PM GMT

    • Contact
    • Contact

      +971 (0) 4 368 1644
      from 8 AM - 5:30 PM GMT

  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR

Maypharm Announces New Product METOX on Times Square in New York
  • USA - español
  • USA - Français
  • Россия - Pусский
  • USA - Deutsch
  • USA - English


News provided by

Maypharm

26 Jan, 2021, 09:00 GMT

Share this article

Share toX

Share this article

Share toX

SEOUL, South Korea and NEW YORK, Jan. 26, 2021 /PRNewswire/ -- Maypharm announces new botulinum toxin, METOX on January 26, 2021. METOX is an effective solution for smoothing any kind of wrinkles from moderate to severe, caused by daily active facial movements.

Maypharm is focusing on outstanding pharmaceutical products to provide superior botulinum toxin product with an up-to-date technological advantage and elaborated advanced manufacturing quality system and sophisticated equipment to meet the GMP requirements of the Agency's CGMP regulations.

Continue Reading
METOX, Maypharm's new botulinum toxin
METOX, Maypharm's new botulinum toxin
Maypharm’s METOX at the Times Square Spectacular Digital Billboard
Maypharm’s METOX at the Times Square Spectacular Digital Billboard

Maypharm successfully entered to a toxin market, announcing their own newly launched toxin on The Times Square Spectacular digital billboard in New York.

Maypharm has already wholesale partners around the world in China, Russia, Europe, US, Middle East and Western Asian countries and regions (Taiwan, Thailand, Vietnam, Philippines) so now is intended to supply METOX, a new toxin worldwide and achieve a strong position in European market and increase significantly a toxin market share within three years of the product launch.

METOX is currently actively conducting clinical trials in various fields for the purpose of treating symptoms such as asymmetry of the jaw muscles and pain in the shoulder muscles, in addition to indications in areas such as improvement of glabellar lines and wrinkles around the eyes.

All existing botulin toxins manufacture their products through the traditional way - lyophilization, there is always some powder residue left on the bottom of every vial. Meanwhile, METOX 100U botulinum toxin A is using a technology of the 2nd generation, an upgraded technique which is called vacuum dehydration. As a result, there is almost no powder residue left on the bottom of every vial. It minimizes denaturalization such as foam or molecular breakage when diluted, making penetration process almost painless and filling via syringe much easier (due to absence of air).

The research showed that METOX development, based on the Latest Equipment & New Standard R&D and due to the 2nd Generation's Technology, in comparison to other products, has a main beneficial point in high purity, stabilization effect, and proven efficacy, which means not only safe procedures of high quality with perfect result, but setting an absolutely New Level in the Global Botulinum Toxin Market.

For more information visit www.maypharm.net

Contact on [email protected] 

Photo - https://mma.prnewswire.com/media/1423400/1st_photo_Metox_image.jpg

Photo - https://mma.prnewswire.com/media/1423908/METOX_small.jpg

Related Links

http://www.maypharm.net

Modal title

Also from this source

MAYPHARM CO., LTD. Launches SKINCOLLA: The World's First Recombinant Human Collagen Filler for Superior Skin Rejuvenation

MAYPHARM CO., LTD. Launches SKINCOLLA: The World's First Recombinant Human Collagen Filler for Superior Skin Rejuvenation

MAYPHARM CO., LTD. proudly introduces SKINCOLLA, the world's first recombinant human collagen filler, marking a significant breakthrough in skin...

Maypharm Unveils Revolutionary Hybrid Filler, Hyalmass Aqua-Exosome: The Future of Skin Hydration and Regeneration

Maypharm Unveils Revolutionary Hybrid Filler, Hyalmass Aqua-Exosome: The Future of Skin Hydration and Regeneration

Maypharm Co., Ltd., a leading innovator in medical and dermo-cosmetic products, proudly introduces the global launch of Hyalmass Aqua-Exosome, a...

المزيد من الإصدارات من هذا المصدر

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Clinical Trials & Medical Discoveries

Clinical Trials & Medical Discoveries

New Products & Services

New Products & Services

المزيد من البيانات الصحفية في مواضيع ذات صلة

Contact PR Newswire

  • +971 (0) 4 368 1644
    from 8 AM - 5:30 PM GMT

Global Sites

  • APAC
  • APAC - Traditional Chinese
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany

 

  • India
  • Indonesia
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland

 

  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921
Global Sites
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States
+971 (0) 4 368 1644
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • Cookie Settings
Copyright © 2025 Cision US Inc.